Are aflibercept biosimilars as safe and effective as the original drug for diabetic macular edema?
Aflibercept is a standard treatment for diabetic macular edema (DME), a condition where fluid builds up in the retina and causes vision loss. Biosimilars are near-identical copies of biologic drugs like aflibercept, designed to be more affordable. The key question is whether these biosimilars work just as well and are as safe as the original. Research shows they are comparable in both effectiveness and safety for DME.
What the research says
A 2024 systematic review and meta-analysis of 11 randomized controlled trials, including 2 studies specifically on DME, found no significant differences between aflibercept biosimilars and the reference drug 4. Changes in best-corrected visual acuity (a measure of vision sharpness) were similar, with a standardized mean difference of 0.11 (95% CI: -0.12 to 0.33) for DME studies, indicating no meaningful difference 4. Central subfield thickness (a measure of retinal swelling) also showed no significant differences between biosimilars and the original 4. Safety outcomes, including treatment-emergent adverse events and ocular adverse effects, were comparable 4. The FDA has approved specific aflibercept biosimilars, such as Pavblu, for DME and other retinal conditions, confirming they meet regulatory standards for safety and efficacy 2. Original aflibercept (Eylea HD) is also FDA-approved for DME 8.
What to ask your doctor
- Are aflibercept biosimilars an option for my DME treatment?
- What are the potential cost savings with a biosimilar compared to the original drug?
- How do the dosing schedules for biosimilars compare to the original aflibercept?
- Are there any specific side effects I should watch for with a biosimilar?
- Can I switch from the original aflibercept to a biosimilar during my treatment?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.